Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1M | -11M | -2M | -5M | -165K |
| EBITDA | -1M | -6M | -5M | -16M | -43K |
| Net Income | -1M | -6M | -6M | -17M | -262K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0103
+0.00% today
1Y Change
-71.43%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stella Diagnostics Inc. (SLDX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 71.4% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -277.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -277.4%, free cash flow -2151.5% with operating margin -196.7% and ROIC 24.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLDX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLDX Max Drawdown
-78.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLDX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$262.1K
+98.4% YoY
Free Cash Flow
-$162.5K
+54.2% YoY
Revenue Growth
+0.0%
EPS Growth
-277.4%
Gross Margin
-40.4%
Net Margin
-227.5%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1M | -11M | -2M | -5M | -165K |
| EBITDA | -1M | -6M | -5M | -16M | -43K |
| Net Income | -1M | -6M | -6M | -17M | -262K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5K | 8K | 1K | 1K | 37K |
| Total Assets | 189K | 472K | 2K | 2K | 40K |
| Total Liabilities | 19M | 18M | 22M | 213M | 11M |
| Shareholder Equity | -19M | -18M | -22M | -213M | -11M |
| Total Debt | 7M | 6M | 8M | 7M | 1M |
| Net Debt | 7M | 6M | 8M | 7M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
163K
+54.2% YoY
Capital Expenditures
4
Free Cash Flow
163K
+54.2% YoY
Key ratios
Gross Margin
-40.4%
Operating Margin
-196.7%
Net Margin
-227.5%
ROE
17.1%
Debt / Equity
-0.46x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.